China is increasingly regarded as a global biotechnology innovation hub, raising strategic concerns in the U.S. According to a report, this growth not only enhances healthcare innovation but also affects pharmaceutical supply chain resilience, economic competitiveness, and national security. The U.S. is reassessing its policies in light of China’s expanding influence, particularly as the value of Chinese drug licensing agreements hit a record US$110 billion in the first half of the year. Meanwhile, Chinese pharmaceutical companies are advancing in manufacturing specialized products. In response, U.S. lawmakers are introducing measures to increase transparency in the pharmaceutical sector to reduce reliance on Chinese technologies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.scmp.com/economy/global-economy/article/3362144/record-chinese-biotech-out-licensing-meets-rising-us-scrutiny
